Tuesday, February 05, 2019 8:13:00 AM
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019 at 9:30 a.m. ET in New York, NY.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group, Inc.
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has a Phase 3 clinical trial planned (pending funding availability) for GPS in acute myeloid leukemia (AML) and is also studying GPS in combination with pembrolizumab in multiple indications. SELLAS has received Orphan Drug designations for GPS from the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA) for AML, malignant pleural mesothelioma (MPM), and multiple myeloma (MM); GPS has also received Fast Track designation for AML, MPM and MM from the FDA. SELLAS’ second product candidate, nelipepimut-S (NeuVax™, NPS), is a HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NPS has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer (TNBC) patients, following standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
https://finance.yahoo.com/news/sellas-life-sciences-present-2019-133000233.html
All posts are speculative and my opinion only. NOT investment advice.
Recent SLS News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:12:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:01:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:42:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:06:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:05:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:01:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:04:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:03:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:02:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:01:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 11:00:13 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/19/2024 09:11:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:07:22 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/05/2024 09:27:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 02:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:21:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:10:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:10:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:07:05 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM